Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Subcutaneous Doses of MOR107 in Healthy Male Subjects and Pharmacodynamics in Healthy Male Subjects on a Low Sodium Diet

Trial Profile

Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Subcutaneous Doses of MOR107 in Healthy Male Subjects and Pharmacodynamics in Healthy Male Subjects on a Low Sodium Diet

Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs MOR 107 (Primary)
  • Indications Diabetic nephropathies; Fibrosis
  • Focus Adverse reactions; First in man
  • Sponsors Lanthio Pharma
  • Most Recent Events

    • 09 Feb 2018 Last checked against ClinicalTrials.gov record.
    • 06 Feb 2018 Status changed from recruiting to discontinued as part 1 was completed successfully and part 2 was not conducted.
    • 03 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top